top of page

SPERO BIOPHARMA

Committed to the Transforming Chronic Disease

Scientist in the Lab
Home: Welcome
Pipetting Samples

BACKGROUND

Spero Biopharma Ltd. was founded by Prof. Marta Weinstock-Rosin, a world-renowned inventor and researcher who invented Exelon®, a blockbuster drug for the treatment of Alzheimer’s disease. Prof Weinstock-Rosin is  professor emeritus at the Hebrew University’s School of Pharmacy-Institute for Drug Research in the Faculty of Medicine.

Home: About Us
Closeup of a Petri Dish

WHAT WE DO

Spero Biopharma’s leading compounds include SPE-100, an innovative treatment for Mild Cognitive Impairment (MCI) which has completed Phase 2 and SPE-200 for NASH.

  • SPE-100

    • provides neuro-protection including by the reduction of microglialactivation and inhibition of pro-inflammatory cytokines

    • Has a rich body of preclinical and clinical data

    • SP-100 has completed a multinational phase-II trial in MCI with positive final results 

  • SPE-200 has rich pre-clinical data and is ready to proceed to Phase 1

  • Spero has a leading team including world class founders and advisory board

  • Broad IP coverage

Home: Our Technology
Microscope

"Big results require big ambitions"

Heraclitus

Home: Quote

GET IN TOUCH

Thanks for submitting!

Home: Contact
bottom of page